Compared with conventional treatment, combined therapy of sodium-glucose co-transporter 2 (SGLT-2) inhibitors and mineralocorticoid-receptor antagonists (MRA) yields significant long-term health outcomes in patients with type 2 diabetes and chronic kidney disease (CKD), according to study findings published in Diabetes, Obesity and Metabolism. Despite findings that demonstrate treatment with angiotensin-converting enzyme (ACE) inhibitors and angiotensin receptor blockers (ARBs) reduces the risk for heart and kidney failure in patients with type 2 diabetes and CKD, these risks remain high. Comp ..read more

Smoking cessation, but not smoking reduction, was associated with decreased incidence of cardiovascular disease (CVD), all-cause mortality, and CVD mortality among patients with type 2 diabetes mellitus (T2DM), according to study findings published in Cardiovascular Diabetology. Investigators explored the association between changes in smoking behavior and risk for CVD incidence and CVD/all-cause mortality among patients with T2DM. An observational cohort study was conducted using data from the Korean National Health Insurance System, comprised of 349,137 patients with T2DM who smoked. A self ..read more

Diabetes remission can be induced following an intensive 12-week metabolic intervention combining insulin glargine/lixisenatide, metformin, and lifestyle approaches, according to study results published in Diabetes, Obesity and Metabolism. Several trials have assessed the effects of lifestyle changes and various combinations of glucose-lowering medications on diabetes remission among patients with type 2 diabetes; however, it is unknown whether combining several therapeutic approaches would increase remission rates and which combinations can be easily followed by patients to sustain remission ..read more

HealthDay News — Among middle-aged female nurses, those reporting an evening chronotype are more likely to have an unhealthy lifestyle, with an increased risk for type 2 diabetes, even after accounting for lifestyle variables, according to a study published online Sept. 12 in the Annals of Internal Medicine. Sina Kianersi, D.V.M., Ph.D., from Brigham and Women’s Hospital and Harvard Medical School in Boston, and colleagues examined the role of modifiable lifestyle behaviors in the association between chronotype and diabetes risk in a prospective cohort study involving 63,676 nurses aged 45 to ..read more

Tirzepatide therapy can lead to weight reduction in patients with diabetes and can be considered an option for managing weight, according to study findings in the International Journal of Obesity. Tirzepatide is the first dual glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) indicated for treating type 2 diabetes. This medication has been shown to reduce weight and other metabolic parameters among patients with diabetes. Researchers conducted a study to determine the safety and efficacy of weight reduction in patients taking tirzepatide.  Data was col ..read more

Nonalcoholic fatty liver disease (NAFLD) with or without nonalcoholic steatohepatitis (NASH) increases the risk for new-onset type 2 diabetes among patients with HIV infection, according to results of a study published in Clinical Infectious Diseases. Researchers conducted a longitudinal cohort study between 2013 and 2022 using data captured from adult patients with HIV infection and no history of excessive alcohol consumption or hepatitis coinfection. The researchers aimed to evaluate the connection between NAFLD (with or without NASH) and the risk for new-onset type 2 diabetes. They also ass ..read more

Type 2 diabetes (T2D) increases the risk for hepatic decompensation and hepatocellular carcinoma (HCC) among patients with nonalcoholic fatty liver disease (NAFLD), according to study findings published in Lancet Gastroenterology & Hepatology. Researchers conducted a systematic review and meta-analysis to determine the risk for hepatic decompensation and HCC among individuals with NAFLD with and without T2D. They searched through databases, including MEDLINE, Cochrane Central Register of Controlled Trials, Cochrane Data of Systematic Reviews, Scopus, Web of Science, and Embase from incepti ..read more

Patients with type 2 diabetes treated with metformin, a glycemic-lowering agent, had a significantly reduced risk of developing long-term dementia, according to study findings published in Alzheimer’s & Dementia. Type 2 diabetes and insulin resistance are known modifiable risk factors for dementia. Antidiabetic drugs, in addition to maintaining euglycemia, may therefore possibly attenuate the development of a major neurocognitive disorder. For the study, researchers aimed to assess the association between metformin and dementia risk and compare this with patients with type 2 diabetes who d ..read more

There is a significantly higher risk for cardiovascular morbidities and mortality among patients with type 2 diabetes (T2D) with microvascular disease vs those without microvascular disease. These findings were published in Cardiovascular Diabetology. Investigators sought to compare risks for macrovascular disease development among patients with T2D with and without microvascular disease. They also compared matched patients with diabetic retinopathy vs diabetic neuropathy, diabetic kidney disease vs diabetic neuropathy, and diabetic kidney disease vs diabetic retinopathy for the same risks. Pr ..read more

HealthDay News — Time-restricted eating (TRE) may help people with type 2 diabetes lose weight, according to a study presented during NUTRITION 2023, the annual meeting of the American Society for Nutrition, held from July 22 to 25 in Boston. Vasiliki Pavlou, R.D., from the University of Illinois Chicago, and colleagues compared the effect of eight-hour TRE, calorie restriction (25 percent), and no intervention (control) on body weight, cardiometabolic risk factors, and glycemic control in 57 randomly assigned adults with type 2 diabetes and overweight or obesity. The researchers found th ..read more